

# Canadian consensus of COVID-19 policy management aspects

## BACKGROUND

As evidence rapidly changes, a need for consensus in hospital policy and management aspects of COVID-19 patient care are needed. This study describes areas where consensus exists and is needed in infection control, and occupational health policy.

### METHOD

Online Survey (May-June 2020) https://forms.gle/t22hDKjQRfesPPDz8




An online survey was sent to the membership of the Association of Medical Microbiology and Infectious Disease (n~700). The survey included questions about COVID-19 patient and outbreak management, personal protective equipment (PPE), and occupational health considerations.

### **DEMOGRAPHICS OF SURVEY PARTICIPANTS (N=28)**


### **Hospital Location**

Number of Survey Participants (n=29)




### **Role in the Hospital**

All survey respondents were infectious disease MD/NP, infection control medical directors, or a medical microbiologist.



### AREAS OF COVID-19 MANAGEMENT LACKING CONSENSUS

### When would you consider removing a patient with COVID-19 from additional precautions? (N=28)



At least 14 days from symptom onset or first positive test whichever is later At least 2 negative NPS (24 h apart) after 14 days from symptom onset or first positive test At least 3 days asymptomatic (excluding post viral cough)

At least 14 days from symptom onset or symptom resolution, whichever is longer

At least 28 days from symptom onset when no follow-up testing is done


### Threshold for outbreak to be declared over (N=25)

At least 14 days from last new case in staff and/or patients whichever is last 28 days from last new case (2 incubation periods) in staf and patients whichever is last


28 days (2 incubation periods) from last new case in patients

14 days from last new case in patients

7 days from last new case in patients (typical symptom onset interval)







- In patient requiring high risk surgery (eg. ENT surgery) to dictate PPE requirements or delay of surgery (64%) Discharging from acute care to LTCF (long term care facilities) (52%) In patients undergoing a planned AGMP (eg. elective intubation) to dictate N95 use (44%)
- Pre-bone marrow transplant recipient (44%)
- Babies born to COVID-19 positive mom (36%) Transfer to acute care from LTCF (long term care facilities) (36%)
- Pre-immunosuppression (32%)
- Pre solid organ donor recipient (32%) Inpatient requiring ongoing AGMP (32%)
- Health care worker returning post exposure to COVID case (28%)
- Pre-bone marrow transplant donor (28%)
- All admissions (28%)
- Pre solid organ donor donor (24%) Chemotherapy patients (20%)
- Labouring or pregnant women (16%)
- Health care worker returning from working at other facilities (eg. long term care facilities) (12%) All staff working on high risk units (12%)

# Kara K. Tsang, Dominik Mertz, Zain Chagla, Fiona Smaill, Sarah Khan

# McMaster University

# N=1

**Potential AGMP Procedure** 

- Intubation, bronchoscopy Bilevel Positive Airway Pressure (BIPAP) / Contin positive airway pressure (CPAP) ebulized medications Ear Nose Throat or Airway/Thoracic procedures High flow nasal cannula (O2) (e.g. AirVo) Care of intubated patients (due to potential ven disconnects) Fransport of intubated patient (staff within 2m) Upper endoscopy Chest tube insertions (if underlying air leak) Caesarean section where risk of imminent intub occur, and surgical team stays in the room Trans-esophageal echocardiography Fransport of intubated patient (airway/head of k Surgeries where aerosolization of non-pulmonar (e.g. Orthopedic bone saw, or laser plume) Induced sputum
- Urgent Procedures where patient is screen posit symptoms, travel

Procedures considered as aerosol generating medical procedures (AGMPs). Respondents (n=28) were allowed to select more than one option. Neck personal protective equipment was not used by 18/22 (66.7%) of respondents, while 4 respondents (18.2%) commented that they use neck prersonal protective equipment only for incubator, code blue stations, or anesthesia.

### PERSONAL PROTECTIVE EQUIPMENT CONSERVATION STRATEGIES

There is universal masking (28/28 respondents) and universal eye protection (16/16 respondents) in place for all clinical staff.

Most respondents (26/28, 92.9%) are using air-purified respirators (PAPRs) for aerosol generating medical procedures.

Of 26 respondents, 15 (57.7%) do not regulate which American Society for Testing and Materials (ASTM) levels of masks that are available in different areas.

PPE Conservation Strategy


No reuse - For single patient encounter only Extended use - Use in between multiple pat Reprocessed and returned back to same use Reprocessed and given to any health care we Maximum duration of use is until becomes visible soiled Planning for potential reprocessing Method of reprocessing: STERIS/STERRAD machine Hydrogen peroxide


Steam UV disinfectant

Personal protective equipment (PPE) conservation strategies (n=28). Not all respondents answered every question. The percentage in brackets was calculated with the number of respondents per question as the denominator. NA corresponds to the question not asked in the survey.


# TREATMENT GUIDELINES

What medical treatment are you recommending or using on severely ill adult (e.g., intubated or multi-organ failure) COVID-19 patients? (N=27)





No guideline Treatment only if enrolled in clinical trial Case by case treatment Lopinavir / Ritonavir Remdesivir



### PROCEDURES CONSIDERED AS AEROSOL GENERATING MEDICAL PROCEDURES

	Number of respondents (%)
	(n=28)
	27 (96.4)
ous	27 (96.4)
	26 (92.9)
	22 (78.6)
	21 (75)
lator	12 (42.9)
	12 (42.9)
	10 (35.7)
	10 (35.7)
tion may	9 (32.1)
	5 (17.9)
ed staff)	3 (10.7)
tissue	3 (10.7)
	1 (3.6)
/e for:	1 (3.6)
	1 (3.6)

	N95 respirators	Surgical masks		
	N (%)	N (%)		
у	9 (37.5)	NA		
tients	13 (48.1)	NA		
er	9 (33.3)	NA		
vorker	15 (55.6)	NA		
wet or	23 (92)	NA		
	13 (54.2)	1 (3.7)		
	12 (60)	0 (0)		
	6 (30)	1 (100)		
	2 (10)	1 (100)		
	3 (15)	1 (100)		

### **COVID-19 NEONATE TESTING (N=13)**

Babies born to COVI

Babies born out

All babies requiring an aeroso

Only one respondent (1/16, 6.3%) tested neonates admitted to their Neonatal Intensive Care Unit regardless of maternal COVID-19 status.

All respondents (15/15, 100%) isolate babies born to COVID-19 positive moms in droplet contact after delivery if NICU care is needed.

positive moms.

Symptoms in a neonate that are an indication for COVID-19 testing are (N=12):

- lower respiratory tract symptoms (100%) - upper respiratory tract symptoms (91.7%)
- fever (91.7%)
- hypothermia (83.3%)
- lymphopenia (66.7%)

### PERSONAL PROTECTIVE EQUIPMENT FOR NEONATES

Most respondents (10/15, 66.7%) are using N95 respirators for all neonates born to COVID-19 positive moms during aerosol generating medical procedures (AGMP) from the initial neonatal resuscitation process. When do you stop using N95 respirators with neonates? (N=9)

If ongoing visits with mom - until mom's COVID-19 status is cleared For duration of admission up to a max of 14 days if separated from mom Only until swab returns negative on baby

### COVID-19 POSITIVE MOMS (N=17)

### For well-babies born to COVID-19 positive moms, they are:

Isolated with positive mom in droplet wearing mask when Isolated with positive mom in droplet

Kept in a separat

A few (3/17) respondents have no restrictions on infant feeding practices of babies born to COVID-19 positive moms. A majority of respondents (13/17, 76.5%) would allow mom to breastfeed while wearing a mask and one respondent restricted baby to have formula/expressed breast milk only.

For COVID-19 positive women in labour, respondents stated that they would allow their partner to be there for vaginal delivery (9/9, 100%) and cesaerian section (6/9, 66.7%).

### SUMMARY

without consensus.

clinical staff.

There is significant variation in practice with respect to discontinuing additional precautions or outbreak measures, asymptomatic testing, aerosol generating medical procedure definitions, personal protective equipment conservation strategies, neonate treatment and testing, and COVID-19 positive mom restrictions.


As evidence evolves, national infection control guidelines will be important to improve standardization of practice and optimize patient care and staff safety.



ID-19 positive moms								92.3%
side of your hospital				30.8%				_
l generating medical procedure		2	23.1%	6				
		1	1		1	1	1	]
C	) 2	2	4		6	8	10	12

No respondents (N=16) have had neonates test COVID-19 positive after being born to COVID-19

- diarrhea (66.7%) - feeding intolerance (50%)
- vomiting (41.7%)
- acute cardiac symptoms (41.7%) - elevated C-reactive protein (CRP) (33.3%)



contact with mom within 2m of infant						82.4%	
contact with mom not wearing mask		11.8%				_	
te room from mom	5.9%						
		1	1	I	I	1	
	0	3	6	9	12	15	

# This survey of Canadian infectious disease MD/NP and infection control medical directors exemplifies areas of COVID-19 policy management aspects with and

Respondents showed consensus in outbreak definitions and universal masking of